Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 4, keine Gesamtzahl für „lenvatinib“
Suchtreffer
Begriffe & Kennungen
Lenvima · 4.8 · Amongst 1,823 patients treated with lenvatinib monotherapy in clinical trials, there were 10 cases (0.5%) of a
Eintrag öffnenLenvima · 4.8 · Blood TSH increased was reported in 12.8% of lenvatinib plus pembrolizumab-treated patients with no patients r
Eintrag öffnenLenvima · 4.8 · Discontinuation of lenvatinib occurred in 30.6% of patients, and discontinuation of both lenvatinib and pembro
Eintrag öffnenLenvima · 4.8 · Dose interruption of lenvatinib due to an adverse reaction occurred in 63.2% of patients. Dose interruption of
Eintrag öffnenLenvima · 4.8 · Dose reduction of lenvatinib due to adverse reactions occurred in 67.0% of patients. The most common (occurrin
Eintrag öffnenLenvima · 4.8 · For additional safety information when lenvatinib is administered in combination, refer to the SmPC for the re
Eintrag öffnenLenvima · 4.8 · In the Phase 3 REFLECT trial (see section 5.1), 7.1% of lenvatinib-treated patients developed a renal failure/
Eintrag öffnenLenvima · 4.8 · In the Phase 3 REFLECT trial (see section 5.1), proteinuria was reported in 26.3% of lenvatinib- treated patie
Eintrag öffnenLenvima · 4.8 · In the Phase 3 REFLECT trial (see section 5.1), there was 1 event of PRES (Grade 2) in the lenvatinib-treated
Eintrag öffnenLenvima · 4.8 · In the Phase 3 Study 309 (see section 5.1), 18.2% of lenvatinib plus pembrolizumab-treated patients developed
Eintrag öffnenLenvima · 4.8 · In the Phase 3 Study 309 (see section 5.1), QT interval prolongation was reported in 3.9% of lenvatinib plus p
Eintrag öffnenLenvima · 4.8 · In the Phase 3 Study 309 (see section 5.1), arterial thromboembolisms were reported in 3.7% of lenvatinib plus
Eintrag öffnenLenvima · 4.8 · In the Phase 3 Study 309 (see section 5.1), cardiac dysfunction was reported in 1.0% of lenvatinib plus pembro
Eintrag öffnenLenvima · 4.8 · In the Phase 3 Study 309 (see section 5.1), diarrhoea was reported in 54.2% of lenvatinib plus pembrolizumab-t
Eintrag öffnenLenvima · 4.8 · In the Phase 3 Study 309 (see section 5.1), events of fistula formation were reported in 2.5% of lenvatinib pl
Eintrag öffnenLenvima · 4.8 · In the Phase 3 Study 309 (see section 5.1), haemorrhage was reported in 24.4% of lenvatinib plus pembrolizumab
Eintrag öffnenLenvima · 4.8 · In the Phase 3 Study 309 (see section 5.1), hepatotoxicity was reported in 33.7% of lenvatinib plus pembrolizu
Eintrag öffnenLenvima · 4.8 · In the Phase 3 Study 309 (see section 5.1), hypertension was reported in 65% of patients in the lenvatinib plu
Eintrag öffnenLenvima · 4.8 · In the Phase 3 Study 309 (see section 5.1), hypocalcaemia was reported in 3.9% of lenvatinib plus pembrolizuma
Eintrag öffnenLenvima · 4.8 · In the Phase 3 Study 309 (see section 5.1), hypothyroidism was reported in 68.2% of lenvatinib plus pembrolizu
Eintrag öffnen